180 Life Sciences announced topline results from a clinical pharmacology study, that evaluated the uptake of cannabidiol in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration, FDA, approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic profile of a generic approved CBD product, Epidiolex, with two solid formulations. The company believes this type of trial has yet to be examined in a clinical setting. For the Company’s trial, twelve volunteers received all three formulations in a crossover randomized trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATNF:
- 180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
- 180 Life Sciences granted additional extension by Nasdaq to regain compliance
- 180 Life Sciences files to sell common stock, warrants, no amount given
- 3 Penny Stocks to Watch Now, 7/11/24
- 180 Life Sciences granted listing compliance extension by Nasdaq